Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
08/2000
08/08/2000US6100387 Chimeric polypeptides containing chemokine domains
08/08/2000US6100377 Aromatically adjusted and confined amino acid sequences; for the development of more efficient synthetic polypeptides
08/08/2000US6100290 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases
08/08/2000US6100282 Thiazole derivatives
08/08/2000US6100277 Retroviral protease inhibitor combinations
08/08/2000US6100271 Compounds which mediate intracellular signaling response to abnormal external stimuli characteristic of diseases; antiinflammatory agents, antifibrotic agents, antisclerotic agents, antitumor agents
08/08/2000US6100266 Hydroxamic and carboxylic acid derivatives
08/08/2000US6100240 Useful as antibacterial agents and antiprotozoa agents
08/08/2000US6100234 Treatment of HIV
08/08/2000US6100088 Viral vaccines
08/08/2000US6100087 Ribozymes targeted to human CCR5 mRNA
08/08/2000US6100065 Recombinant polypeptide particles with high immunogenicity; comprises portion of pre-s1 peptide and surface antigen peptide
08/08/2000US6100037 Polynucleotide encoding a cyclic nucleotide phosphodiesterase having a specific amino acid sequence; diagnosis, treatment, and prevention of cancer and immune disorders; anticarcinogenic/antidiabetic/antiarthritic agents
08/08/2000US6099853 Vaccine containing deactivated bacteria
08/08/2000US6099848 Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
08/08/2000US6099847 Genetic eengineering
08/08/2000US6099840 Variant hbsag protein of fragment thereof displaying the antigenicity of hepatitis b virus surface antigen
08/08/2000US6099839 Gonococcal anti-idiotypic antibodies and methods compositions using them
08/08/2000US6099835 Method of using antiviral composition
08/08/2000CA2185019C Isoxazoline compounds as inhibitors of tnf release
08/08/2000CA2157479C Method of treating hepatitis c in non-responders to interferon treatment
08/08/2000CA2125376C Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
08/08/2000CA1341074C Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
08/03/2000WO2000045177A1 Assays for modulators of elongation factor p activity
08/03/2000WO2000045167A2 Non-invasive method for detecting target rna
08/03/2000WO2000044912A1 Manipulating isoprenoid expression
08/03/2000WO2000044906A2 GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
08/03/2000WO2000044904A1 Basb059 polypeptides from neisseria meningitidis
08/03/2000WO2000044897A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000WO2000044895A1 Method and medicament for inhibiting the expression of a defined gene
08/03/2000WO2000044894A1 Method for isolating apoptosis-inducing dna sequences and detection system
08/03/2000WO2000044888A2 Dimethylarginine dimethylaminohydrolases
08/03/2000WO2000044884A1 Bhv-1 gene-deleted virus vaccine
08/03/2000WO2000044763A2 Compositions for treating inflammatory response
08/03/2000WO2000044761A2 Ketolide antibiotics
08/03/2000WO2000044750A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
08/03/2000WO2000044749A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
08/03/2000WO2000044741A2 Process to prepare cyclic-sulfur fluorine containing oxazolidinones
08/03/2000WO2000044740A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044730A1 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000WO2000044729A1 Crystalline quinoxaline derivative
08/03/2000WO2000044727A1 Inhibitors for the biosynthesis of vitamin b2 and method for producing same
08/03/2000WO2000044716A1 Acetylenic sulfonamide thiol tace inhibitors
08/03/2000WO2000044713A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
08/03/2000WO2000044711A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044710A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044709A2 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044406A2 Dna vaccines against hantavirus infections
08/03/2000WO2000044405A1 Dmsa promoters and derivatives thereof used for controlled expression of foreign genes
08/03/2000WO2000044402A1 Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
08/03/2000WO2000044392A2 Identification of specific differentially expressed mycobacterial antigens
08/03/2000WO2000044388A1 Modulation of immune response by ribavirin
08/03/2000WO2000044373A1 Antibacterial hydroxamic acid derivatives
08/03/2000WO2000044371A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000WO2000044358A2 Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections
08/03/2000WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000WO2000044230A1 A method of controlling fungal pathogens, and agents useful for same
08/03/2000WO2000028947A3 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
08/03/2000WO2000024896A3 Biological material for preparing pharmaceutical compositions for treating mammals
08/03/2000WO2000023407A3 Ureido-thiobutyric acid derivatives as ppar-agonists
08/03/2000WO2000023105A3 Adjuvant systems and vaccines
08/03/2000WO2000020609A3 Protective recombinant haemophilus influenzae high molecular weight proteins
08/03/2000WO2000014240A3 Attenuated salmonella sp12 mutants as antigen carriers
08/03/2000WO2000009550A9 Vanadate resistance glycosylation 4 gene
08/03/2000WO2000008051A3 Immunological herpes simplex virus antigens and methods for use thereof
08/03/2000WO2000006589A9 Prostate derived ets factor
08/03/2000WO1999063975A3 A method for stimulating the immune system
08/03/2000WO1999055366A8 Chimeras of hepatitis c virus and bovine viral diarrhea virus
08/03/2000WO1999026942A8 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
08/03/2000WO1999015130A3 Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
08/03/2000DE19903736A1 Inhibitoren der Biosynthese von Vitamin B2 und Verfahren zu ihrer Herstellung Inhibitors of the biosynthesis of vitamin B2 and process for their preparation
08/03/2000DE19902924A1 Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen Use of organophosphorus compounds in the prophylactic and therapeutic treatment of infections
08/03/2000CA2363565A1 Basb059 polypeptides from neisseria meningitidis
08/03/2000CA2361614E Compositions for treating inflammatory response
08/03/2000CA2361518A1 Purine inhibitors of cyclin dependent kinase 2 and ikb-.alpha.
08/03/2000CA2361246A1 Identification of specific differentially expressed antigens
08/03/2000CA2360997A1 Non-invasive method for detecting target rna
08/03/2000CA2360674A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000CA2360661A1 Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections
08/03/2000CA2360643A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000CA2360600A1 A method of controlling fungal pathogens, and agents useful for same
08/03/2000CA2360334A1 Manipulating isoprenoid expression
08/03/2000CA2360085A1 Genes identified as required for proliferation in escherichia coli
08/03/2000CA2359711A1 Process to prepare cyclic-sulfur fluorine containing oxazolidinones
08/03/2000CA2359317A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000CA2357735A1 Modulation of immune response by ribavirin
08/03/2000CA2356855A1 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356481A1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356480A1 Acetylenic sulfonamide thiol tace inhibitors
08/03/2000CA2356346A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
08/03/2000CA2356345A1 Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356313A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
08/03/2000CA2356299A1 Acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid tace inhibitors
08/03/2000CA2356267A1 2,3,4,5-tetrahydro-1h-¬1,4|benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000CA2355735A1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
08/02/2000EP1024189A1 Novel antigenic class of avian reoviruses
08/02/2000EP1024145A2 Novel azalides and methods of making same
08/02/2000EP1023904A2 Adjuvants for use in vaccines
08/02/2000EP1023903A1 Use of life attenuated bacteria for the manufacture of a submucosal vaccine
08/02/2000EP1023605A1 Methods and compositions for detecting hepatitis e virus
1 ... 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 ... 1798